Calithera is developing targeted small molecules to disrupt tumor metabolism. Telaglenastat, a glutaminase inhibitor, in combination with chemoimmunotherapy is being evaluated in a randomized 1L trial in patients with NSCLC with KEAP1/NRF2 mutations.